"People buy outcomes, not features." This marketing maxim, while a staple of sales training, is perhaps the most overlooked filter in the world of growth investing. For decades, retail and institutional investors alike have fallen into the 'technical trap,' obsessing over clock speeds, patent counts, and incremental hardware improvements. They analyze the 'features' of a business—the nuts and bolts of what it makes—while ignoring the 'outcome'—what it actually achieves for the end user. In the hyper-competitive markets of 2026, the distinction between these two perspectives is not just academic; it is the difference between capturing a 10x return and watching a value trap slowly erode your capital.
The Fallacy of the Spec Sheet
History is littered with technically superior products that failed to capture market share because they focused on features over outcomes. In the early 2000s, specialized MP3 players boasted more storage and better audio fidelity than the early iPod, yet Apple (AAPL) won because it sold the outcome of '1,000 songs in your pocket.' Fast forward to the semiconductor wars of the early 2020s. For years, critics argued that NVIDIA (NVDA) was overvalued because its chips were more expensive and power-hungry than rivals. They were looking at the features. The market, however, began to price in the outcome: the ability to train large language models in weeks rather than years. By 2024, when NVIDIA’s market cap surged past $3 trillion, it wasn't because they had the best specs in a vacuum; it was because they owned the only viable outcome for the generative AI revolution.
Investors who fixated on Intel’s (INTC) massive manufacturing footprint or its legacy x86 dominance were buying features. They were buying 'the way things have always been done.' Meanwhile, the alpha was generated by those who recognized that the world no longer needed just faster CPUs; it needed the outcome of accelerated computing. This is the provocative reality of growth investing: the 'best' technology rarely wins. The technology that delivers the most frictionless, valuable result is the one that captures the premium multiple.
Selling the Promised Land
To identify the next generational growth story, one must look at companies that sell 'The Promised Land.' Consider the Software-as-a-Service (SaaS) sector. The reason companies like Salesforce (CRM) or ServiceNow (NOW) maintained high double-digit growth rates for over a decade is that they stopped selling software 'features'—like database management or ticket tracking—and started selling the outcome of 'digital transformation' and 'operational efficiency.' When a CEO signs a $10 million contract with ServiceNow, they aren't buying a cloud platform; they are buying the outcome of a reduced headcount and a streamlined workflow.
This shift in perspective allows these companies to command pricing power that defies traditional valuation models. If you view a company through the lens of its features, you will always find it 'expensive' relative to its peers. But if you view it through the lens of the outcome it provides—especially if that outcome is mission-critical—the valuation starts to look like a bargain. For example, during the 2022 market correction, many analysts claimed Tesla (TSLA) was just a car company with a few tech features. They missed the outcome: Tesla was selling a status symbol integrated into a proprietary energy ecosystem. People weren't buying a battery with 400 miles of range; they were buying the outcome of prestige and 'future-proofing' their lifestyle.
The Valuation of Inevitability
Growth investing requires the courage to pay for the 'inevitability' of an outcome. When a company successfully shifts the market's focus from what it does to what it achieves, it creates a moat that is nearly impossible to breach. This is why we see 'winner-take-most' dynamics in the modern economy. Once a company becomes the standard-bearer for a specific outcome—think Amazon (AMZN) for 'instant gratification' or Google (GOOGL) for 'universal information'—the features of their competitors become irrelevant.
As an investor, your task is to identify where the 'feature-to-outcome' transition is currently happening. We see this today in the biotech sector, where companies are moving away from selling 'treatments' (features) to selling 'cures' (outcomes) via gene editing. We see it in fintech, where the winners aren't those with the best app interface, but those who deliver the outcome of 'financial sovereignty.' Stop looking at the spec sheet. Stop worrying about whether a product has ten more bells and whistles than its competitor. Ask yourself: what is the fundamental transformation this company offers? If the outcome is transformative, the features are just details—and the growth potential is likely far higher than the current price reflects.